Nurix Therapeutics has been granted a patent for compounds, compositions, and methods to inhibit the E3 enzyme Cbl-b in the ubiquitin proteasome pathway. The patent covers using Cbl-b inhibitors to modulate the immune system, treat diseases, and develop cancer treatments involving vaccines and oncolytic viruses. GlobalData’s report on Nurix Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Nurix Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Nurix Therapeutics's grant share as of May 2024 was 6%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for cbl-b inhibitors for immune system modulation
A recently granted patent (Publication Number: US11951133B2) discloses a method for modulating the activity of immune cells by contacting them with a Cbl-b inhibitor, a compound of Formula (I). The immune cells targeted in this method include T-cells, B-cells, natural killer (NK)-cells, and tumor infiltrating lymphocytes (TIL) isolated from cancerous tumors. The modulation of immune cell activity involves enhancing T-cell activation, proliferation, and reducing exhaustion and tolerance. This method also includes culturing immune cells with specific antibodies and cytokines to achieve desired outcomes.
Furthermore, the patent covers the production of modified immune cells by culturing cell populations with Cbl-b inhibitors, as well as methods for modulating immune responses, inhibiting abnormal cell proliferation, and treating conditions associated with Cbl-b activity. The patent also includes pharmaceutical compositions, kits, and methods specifically tailored for treating cancer by administering small molecule Cbl-b inhibitors of Formula (I). These innovative methods and compositions offer promising avenues for enhancing immune responses, inhibiting abnormal cell proliferation, and treating cancer by targeting Cbl-b activity effectively.
To know more about GlobalData’s detailed insights on Nurix Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
